Dementia

A protein thought to play a critical role in the progression of Alzheimer’s disease may not originate where scientists thought, which could mean we may have to reconsider how we approach fighting this form of deadly neurodegeneration.

Developed by researchers in the US, the remarkable new treatment could one day be used to treat patients in advanced stages of dementia by restoring the brain’s ability to recover from ongoing neurodegeneration.

Cognitive decline is far more common among individuals over the age of 65 years, but some genetic mutations cause the same characteristic loss of memory and mental processing in children. But the good news is that we now know how to treat it.

In a move that could drastically help slow the progression of Alzheimer's Disease (AD), the FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as young as 40 years who have shown potential cognitive symptoms of the condition.